Company Filing History:
3 out of 541 
Years Active: 2018-2024
Title: Lorraine Irving: Innovator in Therapeutic Binding Molecules
Introduction
Lorraine Irving is a distinguished inventor based in Cambridge, GB. She has made significant contributions to the field of therapeutic binding molecules, with a focus on innovative treatments for various diseases. With a total of 4 patents, her work has the potential to impact the medical community profoundly.
Latest Patents
One of her latest patents involves therapeutic binding molecules that specifically target the chemokine receptor CCR9. This invention is particularly relevant for the treatment of CCR9-mediated diseases, such as inflammatory bowel disease (IBD). The methods for detecting CCR9 using these binding molecules are also noteworthy. Another significant patent focuses on antibodies that bind to human α-synuclein with high affinity. This invention aims to reduce α-synuclein spreading in vivo and provides methods for generating antibodies that can be used in treating diseases of the central nervous system, particularly alpha-synucleinopathies.
Career Highlights
Lorraine Irving is currently associated with Medimmune Limited, where she continues to advance her research and development efforts. Her work has garnered attention for its innovative approach to addressing complex medical conditions.
Collaborations
Throughout her career, Lorraine has collaborated with notable colleagues, including Darren Schofield and Michael Perkinton. These partnerships have contributed to her success and the advancement of her research.
Conclusion
Lorraine Irving stands out as a pioneering inventor in the field of therapeutic binding molecules. Her contributions are paving the way for new treatments and methodologies in medicine.